12/3
06:31 pm
supn
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference [Yahoo! Finance]
Low
Report
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference [Yahoo! Finance]
12/3
04:05 pm
supn
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
Low
Report
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
11/26
02:19 pm
supn
Supernus Pharmaceuticals (NASDAQ:SUPN) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Supernus Pharmaceuticals (NASDAQ:SUPN) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
11/24
06:21 pm
supn
Assessing Supernus Pharmaceuticals After FDA Pipeline News and 24% Jump in 2025 [Yahoo! Finance]
Low
Report
Assessing Supernus Pharmaceuticals After FDA Pipeline News and 24% Jump in 2025 [Yahoo! Finance]
11/21
06:11 pm
supn
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/21
04:06 pm
supn
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
11/12
04:05 pm
supn
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
Low
Report
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
11/12
01:54 pm
supn
MERGE Wins Modern Healthcare x Ad Age Healthcare Marketing Impact Award: Agency of the Year [Yahoo! Finance]
Low
Report
MERGE Wins Modern Healthcare x Ad Age Healthcare Marketing Impact Award: Agency of the Year [Yahoo! Finance]
11/8
01:17 pm
supn
Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by analysts at
Wall
Low
Report
Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by analysts at
Wall
11/6
09:41 am
supn
Supernus Pharmaceuticals (SUPN) Profit Margin Soars, Challenging Cautious Earnings Narratives [Yahoo! Finance]
Low
Report
Supernus Pharmaceuticals (SUPN) Profit Margin Soars, Challenging Cautious Earnings Narratives [Yahoo! Finance]
11/6
08:23 am
supn
Supernus Pharmaceuticals (SUPN) is Benefiting from Its Strength in Financial Position [Yahoo! Finance]
Low
Report
Supernus Pharmaceuticals (SUPN) is Benefiting from Its Strength in Financial Position [Yahoo! Finance]
11/4
04:01 pm
supn
Supernus Announces Third Quarter 2025 Financial Results
High
Report
Supernus Announces Third Quarter 2025 Financial Results
10/29
08:08 am
supn
Supernus Pharmaceuticals (NASDAQ:SUPN) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $65.00 price target on the stock.
Low
Report
Supernus Pharmaceuticals (NASDAQ:SUPN) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $65.00 price target on the stock.
10/24
08:10 pm
supn
A Look at Supernus Pharmaceuticals (SUPN) Valuation After a 55% Three-Month Share Price Surge [Yahoo! Finance]
Low
Report
A Look at Supernus Pharmaceuticals (SUPN) Valuation After a 55% Three-Month Share Price Surge [Yahoo! Finance]
10/23
11:51 am
supn
Supernus Pharmaceuticals (NASDAQ:SUPN) had its price target raised by analysts at TD Cowen from $45.00 to $60.00. They now have a "buy" rating on the stock.
Low
Report
Supernus Pharmaceuticals (NASDAQ:SUPN) had its price target raised by analysts at TD Cowen from $45.00 to $60.00. They now have a "buy" rating on the stock.
10/21
05:20 pm
supn
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 [Yahoo! Finance]
Neutral
Report
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 [Yahoo! Finance]
10/21
05:00 pm
supn
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
Neutral
Report
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
10/13
03:57 am
supn
Branded Pharmaceuticals Stocks Q2 Earnings Review: Supernus Pharmaceuticals (NASDAQ:SUPN) Shines [Yahoo! Finance]
Low
Report
Branded Pharmaceuticals Stocks Q2 Earnings Review: Supernus Pharmaceuticals (NASDAQ:SUPN) Shines [Yahoo! Finance]
10/9
08:07 am
supn
Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $65.00 price target on the stock, up previously from $40.00.
Low
Report
Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $65.00 price target on the stock, up previously from $40.00.
10/9
03:33 am
supn
Q2 Earnings Highs And Lows: Organon (NYSE:OGN) Vs The Rest Of The Branded Pharmaceuticals Stocks [Yahoo! Finance]
Low
Report
Q2 Earnings Highs And Lows: Organon (NYSE:OGN) Vs The Rest Of The Branded Pharmaceuticals Stocks [Yahoo! Finance]
10/4
12:06 am
supn
Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by analysts at
Wal
Low
Report
Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by analysts at
Wal
10/3
03:45 pm
supn
Supernus Pharmaceuticals (NASDAQ:SUPN) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Supernus Pharmaceuticals (NASDAQ:SUPN) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
9/30
10:18 am
supn
Supernus Pharmaceuticals (NASDAQ:SUPN) had its price target raised by analysts at Cantor Fitzgerald from $46.00 to $63.00. They now have an "overweight" rating on the stock.
Low
Report
Supernus Pharmaceuticals (NASDAQ:SUPN) had its price target raised by analysts at Cantor Fitzgerald from $46.00 to $63.00. They now have an "overweight" rating on the stock.
9/22
11:27 am
supn
Parkinson's Disease Therapeutics Market Size to Hit US$ 12.83 Billion by 2033, Report by DataM Intelligence [Yahoo! Finance]
Low
Report
Parkinson's Disease Therapeutics Market Size to Hit US$ 12.83 Billion by 2033, Report by DataM Intelligence [Yahoo! Finance]
9/19
06:26 am
supn
Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.